Westwood Holdings Group Inc. decreased its position in Becton Dickinson and Co (NYSE:BDX) by 31.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 457,999 shares of the medical instruments supplier’s stock after selling 210,976 shares during the quarter. Becton Dickinson and accounts for approximately 1.3% of Westwood Holdings Group Inc.’s holdings, making the stock its 13th largest holding. Westwood Holdings Group Inc. owned 0.17% of Becton Dickinson and worth $115,420,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $25,000. Hexavest Inc. acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $28,000. Lipe & Dalton acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $28,000. Mcmillion Capital Management Inc. acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $40,000. Finally, Financial Gravity Wealth Inc. raised its stake in shares of Becton Dickinson and by 81.5% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 167 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares during the period. 84.21% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the transaction, the chief executive officer now owns 218,671 shares in the company, valued at $56,937,554.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James C. Lim sold 9,299 shares of Becton Dickinson and stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $263.53, for a total value of $2,450,565.47. Following the transaction, the executive vice president now owns 33,041 shares of the company’s stock, valued at approximately $8,707,294.73. The disclosure for this sale can be found here. Insiders have sold 37,249 shares of company stock valued at $9,616,803 in the last quarter. 0.12% of the stock is currently owned by corporate insiders.

Several analysts have issued reports on the company. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Raymond James lifted their target price on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co lifted their target price on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Finally, Piper Jaffray Companies lowered their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $266.55.

Shares of NYSE:BDX traded down $2.62 during midday trading on Friday, reaching $253.76. The company had a trading volume of 70,585 shares, compared to its average volume of 914,994. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The business’s 50 day moving average price is $252.97 and its 200 day moving average price is $245.64. The stock has a market cap of $69.69 billion, a PE ratio of 23.07, a P/E/G ratio of 1.83 and a beta of 1.13. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the previous year, the business earned $2.91 earnings per share. Becton Dickinson and’s quarterly revenue was up 1.7% on a year-over-year basis. On average, research analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is currently 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.